

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT ENTERING INTO T-CELL ENGAGER DISCOVERY COLLABORATION WITH CANDID

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Nona Biosciences (Suzhou) Co., Ltd (“**Nona Biosciences**”), a subsidiary wholly-owned by the Company, and Candid Therapeutics, Inc. (“**Candid**”) have entered into a research collaboration and license agreement (the “**Agreement**”) to discover next-generation T-cell engagers (the “**Product**”). Pursuant to the Agreement, Nona Biosciences will be eligible to receive upfront and potential milestone payments of up to US\$320 million. Candid will be responsible for all subsequent development of the Product.

About Candid Therapeutics, Inc.

Candid Therapeutics, Inc. is a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for B-cell depletion to treat autoimmune diseases. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors.

Cautionary Statement: The Company cannot guarantee that it will be able to successfully develop or ultimately market its products referenced in the announcement. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 16 December 2024

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive directors; Ms. Weiwei Chen as a non-executive director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Dr. Albert R. Collinson as independent non-executive directors.